Transaction DateRecipientSharesTypePriceValue
3rd September 2020Stephen Richard9,310Grant/award etc.$0.00
3rd September 2020John B Iii Henneman9,310Grant/award etc.$0.00
6th August 2020Richard Hague8,545Payment by withholding$1.60$13,672.00
5th August 2020John B Iii Henneman10,000Open or private sale$15.00$150,000.00
16th July 2020Richard Hague10,546Payment by withholding$1.52$16,029.92
9th July 2020James Loerop1,244Open or private sale$35.15$43,726.60
8th July 2020James Loerop3,000Grant/award etc.$0.00
26th June 2020Richard Hague5,283Payment by withholding$1.37$7,237.71
3rd June 2020John B Iii Henneman8,488Grant/award etc.$0.00
26th May 2020Cheryl R Blanchard30,000Grant/award etc.$0.00
Anika Therapeutics
Anika Therapeutics logo

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company. The company develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.

Ticker: ANIK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 898437
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $117 M (-25%)
Marketable Securities, Current: $28 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $221 M (-5%)
Property, Plant and Equipment, Net: $53 M (3%)
Other Assets, Noncurrent: $13 M (79%)
Assets: $441 M (33%)
Accounts Payable, Current: $6 M (60%)
Liabilities, Current: $28 M (71%)
Other Liabilities, Noncurrent: $843 Th (136%)
Common Stock, Value, Issued: $142 Th (0%)
Common Stock, Shares, Issued: $14 Th (0%)
Additional Paid in Capital, Common Stock: $51 M (3%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $6 M (-1%)
Stockholders' Equity (Parent): $288 M (0%)
Liabilities and Equity: $441 M (33%)
Revenue: $31 M (0%)
Cost of Revenue: $17 M (-45%)
Research and Development: $5 M (-57%)
Operating Income/Loss: $10 M (290%)
Provision for income taxes: $2 M (0%)
EPS (basic): $0.54 (315%)
EPS (diluted): $0.54 (315%)